{"ATC Code":["N - Nervous system","N05 - Psycholeptics","N05A - Antipsychotics","N05AX - Other antipsychotics","N05AX12","N05AX12 - Aripiprazole","QN - Nervous system","QN05 - Psycholeptics","QN05A - Antipsychotics","QN05AX - Other antipsychotics","QN05AX12 - Aripiprazole"],"Absorption, Distribution and Excretion":"Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%. ABILIFY can be administered with or without food. Administration of a 15 mg ABILIFY tablet with a standard high-fat meal did not significantly affect the Cmax or AUC of aripiprazole or its active metabolite, dehydro-aripiprazole, but delayed Tmax by 3 hours for aripiprazole and 12 hours for dehydro-aripiprazole.  Oral Solution: Aripiprazole is well absorbed when administered orally as the solution. At equivalent doses, the plasma concentrations of aripiprazole from the solution were higher than that from the tablet formulation. In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution-to-tablet ratios of geometric mean Cmax and AUC values were 122% and 114%, respectively. The single-dose pharmacokinetics of aripiprazole were linear and dose-proportional between the doses of 5 mg to 30 mg.   Extended-release injectable suspension, bimonthly injection: Aripiprazole absorption into the systemic circulation is prolonged following gluteal intramuscular injection due to the low solubility of aripiprazole particles. The release profile of aripiprazole from ABILIFY ASIMTUFII results in sustained plasma concentrations over 2 months following gluteal injection(s). Following multiple doses, the median peak:trough ratio for aripiprazole following an ABILIFY ASIMTUFII dose is 1.3, resulting in a flat plasma concentration profile with Tmax ranging between 1 to 49 days following multiple gluteal administrations of 960 mg.","Adverse Effects":"Although the side effects of aripiprazole are similar to those found in typical and atypical antipsychotics, the degree of extrapyramidal symptoms (EPS) and metabolic syndromes are less due to receptor specificity. EPS such as akathisia, parkinsonian features such as resting tremor and shuffling gait, acute dystonic reactions, oculogyric crises, opisthotonos, and tardive dyskinesia are manageable with benztropine or sodium benzoate. Aripiprazole is associated with lower incidences of weight gain, hypercholesterolemia, glucose dysregulation, cardiovascular abnormalities, and hyperprolactinemia. Hyperprolactinemia may manifest as galactorrhea, gynecomastia in men, sexual dysfunction, amenorrhea, or off-cycle bleeding. Other possible side effects of aripiprazole include somnolence, nausea, vomiting, akathisia, and lightheadedness. Antipsychotics agent use requires caution in older adults because it can cause or exacerbate the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; thus, it is crucial to monitor sodium during initiation and dosage adjustment. Children and adolescents are more susceptible than older patients to experience EPS, weight gain, and other metabolic side effects. The FDA also recently identified an association between aripiprazole use and compulsive or uncontrollable urges to engage in sex, gamble, binge eat, and shopping.","Aliases":["Abilify","Abilitat","OPC-14597","Abilify Discmelt","aripiprazol","Discmelt","Opc 14597","Aripiprex","Abilify MyCite","OPC 31","OPC-31","Abilify Maintena","aripiprazolum","7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1h)-one","7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone","Abilify Maintena Kit","2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-","NSC-759266","Dtxsid3046083","7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone","7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone","7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one","Abilify mycite kit","7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one","Dtxcid1026083","Chebi:31236","2(1H)-Quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-","Abilify asimtufii","Aripiprazole oral","7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1,2,3,4-tetrahydroquinolin-2-one","7-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy)-3,4-dihydroquinolin-2(1H)-one","OPIPZA","Aripiprazole orally disintegrating","N05AX12","603-355-5","C23H27Cl2N3O2","AriprazoleImpurity","7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril","CHEMBL1112","7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril","Mfcd00892072","Ncgc00159510-02","1026778-41-5","7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one","Smr000466383","Cas-129722-12-9","HSDB 7320","Sr-01000759353","Unii-82vfr53i78","Abilify Digital","7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy)-3,4-dihydrocarbostyril","7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril","Abilify OD","Aripiprazole CRS","Aripiprazole Depot","9SC","MEZOFY","BMS-337039","KS-1030","Cpd000466383","GTPL34","Schembl8255","Aripiprazole Crystal Form I","Mls000759517","Mls001165779","Mls001195621","Mls001424078","Mls006011892","orb1308154","orb3012994","orb3141214","Aristada","Schembl12961254","Schembl29356997","Schembl29438823","Schembl29475637","Schembl29475638","Aripiprazole - Bio-X trade mark","GLXC-06844","HMS2051I18","HMS2089M20","HMS2093F22","HMS2230M18","HMS3373D04","HMS3393I18","HMS3657K13","HMS3715J07","HMS3744A13","HMS3884E18","HMS5080H11","Pharmakon1600-01505851","MSK10169","PTB11506","Tox21_111728","Aripiprazole, 1mg/ml in Acetonitrile","BBL029082","Bdbm50130293","178","EBC-12081","HY-14546R","NSC759266","s1975","STK625160","Akos005558247","Tox21_111728_1","AB07660","AC-1554","CCG-100891","CS-0766","DB01238","FA17978","NC00141","NSC 759266","Aripiprazole 1.0 mg/ml in Acetonitrile","PS25 - Aripiprazole/Dehydroaripiprazole","Ncgc00159510-03","Ncgc00159510-04","Ncgc00159510-05","BA164218","HY-14546","SY053146","Sbi-0206870.p001","A2496","NS00001912","SW197521-3","D01164","En300-119521","Ab00639935-09","Ab00639935_10","Ab00639935_11","L001339","Sr-01000759353-4","Sr-01000759353-6","Brd-k70358946-001-06-6","Brd-k70358946-001-14-0","Brd-k70358946-001-15-7","Z1521553846","7-[4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone","7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]Butoxy]3,4-Dihydro-2(1H)-Quinolinone","7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-quinolin-2(1H)-one","7-{4-[-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril","7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinol in-2-one","7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one","7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3, 4-dihydrocarbostyril","aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril","24-29-3"],"Biological Half-Life":"The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively. For populations that are poor CYP2D6 metabolizers, the half-life of aripiprazole is 146 hours and these patients should be treated with half the normal dose. Other studies have reported a half-life of 61.03±19.59 hours for aripiprazole and 279±299 hours for the active metabolite.","Boiling Point":"139.0-139.5 °C","CAS":"129722-12-9","ChemicalClasses":["phenylpropylamine"],"Chirality":"achiral","Color/Form":"Colorless, flake crystals from ethanol","Drug Classes":["Breast Feeding","Lactation","Milk, Human","Antipsychotic Agents"],"Drug Indication":"Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.","Drug Warnings":"/BOXED WARNING/ WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. ABILIFY (aripiprazole) is not approved for the treatment of patients with dementia-related psychosis. /Included in label/","DurationOfAction":"","EliminationHalfLife":"75 hours (active metabolite is 94 hours)","Erowid Experience Reports":[{"Author":"Meat","Id":29637,"Title":"The Sick Combo"},{"Author":"Herbivore","Id":85867,"Title":"Diminished Effects"},{"Author":"Melly","Id":92689,"Title":"A Strange Time Indeed"},{"Author":"Cheddar","Id":72929,"Title":"Worthless"},{"Author":"psycholizard","Id":110682,"Title":"I Feel Literally Nothing When I Smoke"},{"Author":"cosmicslide","Id":92233,"Title":"The Second Atypical"},{"Author":"Ethan J.","Id":110448,"Title":"Used for Delusional Episode"},{"Author":"Mj","Id":110707,"Title":"Latuda and Other Drugs"},{"Author":"Mj","Id":112124,"Title":"All I Wanted to Do Was Sleep"},{"Author":"Feather E.","Id":113596,"Title":"The Possibility of a Decrease in Effect"},{"Author":"Yoshi","Id":114124,"Title":"Extreme Restlessness"},{"Author":"Shadowboxer7777","Id":84695,"Title":"From One Schizophrenic to Another"},{"Author":"Bigredox","Id":81238,"Title":"Interfering With Other Drugs"},{"Author":"Raquel","Id":79887,"Title":"Like a Sugar High"},{"Author":"Rick","Id":54812,"Title":"The Social Contract"},{"Author":"Voo","Id":66018,"Title":"Methamphetamine and Anti-Psychotics"},{"Author":"far2farside8","Id":74305,"Title":"Poor Luck with Newer Atypical Antipsychotic"},{"Author":"doctorfur","Id":119019,"Title":"The Anti Psychotic for Autism"},{"Author":"SayMe","Id":79355,"Title":"Disgusting With Potential?"},{"Author":"Pretentions","Id":77422,"Title":"Losing My Ability to Calm Down"},{"Author":"Wasted Dreams","Id":116603,"Title":"The Maw - Daily Bipolar Cocktail and Wean"},{"Author":"4kg dumbbell","Id":115958,"Title":"Excrutiating Discomfort"},{"Author":"Walter Od","Id":113397,"Title":"Oculogyric Crisis"},{"Author":"yellowtail","Id":94998,"Title":"Being a Narcoleptic"},{"Author":"Injun","Id":57716,"Title":"Emotions Tied Up in Goo"},{"Author":"Kippzy","Id":69506,"Title":"A Day of Hell I'll Never Forget"}],"Esters":[],"European Community (EC) Number":"603-355-5","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"82VFR53I78"}]}},{"Name":"Active Moiety","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"ARIPIPRAZOLE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Atypical Antipsychotic"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-60795","Length":12,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Aripiprazole"}],"String":"Aripiprazole is an Atypical Antipsychotic."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":80,"Value":{"StringWithMarkup":[{"String":"ARIPIPRAZOLE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":80,"Value":{"StringWithMarkup":[{"String":"Atypical Antipsychotic [EPC]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":81,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-60795","Length":12,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/ARIPIPRAZOLE"}],"String":"ARIPIPRAZOLE ORALLY DISINTEGRATING"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":81,"Value":{"StringWithMarkup":[{"String":"Atypical Antipsychotic [EPC]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":82,"Value":{"StringWithMarkup":[{"String":"ARIPIPRAZOLE ORAL"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":82,"Value":{"StringWithMarkup":[{"String":"Atypical Antipsychotic [EPC]"}]}}],"Formating":[],"HMDB ID":"HMDB0005042","Health Effects":"Health effetcs include hyperpyrexia,muscle rigidity,altered mental status,and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Other effects may include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology (RxList, A308).","HeavyAtomCount":30,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents","IUPACName":"7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one","InChI":"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)","InChIKey":"CEUORZQYGODEFX-UHFFFAOYSA-N","Interactions":"Substrates of Hepatic Microsomal Enzymes: Substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4; pharmacokinetic interaction unlikely.","KEGG Entries":[{"Id":"D01164","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole","Abilify"]},{"Id":"D10364","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole lauroxil","Aristada"]},{"Id":"D10516","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole hydrate","Aripiprazole monohydrate","Abilify maintena"]},{"Id":"D01164","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole","Abilify"]},{"Id":"D10516","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole hydrate","Aripiprazole monohydrate","Abilify maintena"]},{"Id":"D01164","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole","Abilify"]},{"Id":"D10364","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole lauroxil","Aristada"]},{"Id":"D10516","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP2D6"},{"Action":"induction","Target":"CYP2D6"}],"Synonyms":["Aripiprazole hydrate","Aripiprazole monohydrate","Abilify maintena"]}],"MeSH Headers":[{"Id":"M000602020","Link":"https://id.nlm.nih.gov/mesh/M000602020.html","Name":"Aripiprazole","Ref":119},{"Id":"M000602022","Link":"https://id.nlm.nih.gov/mesh/M000602022.html","Name":"Abilify","Ref":121},{"Id":"M0249360","Link":"https://id.nlm.nih.gov/mesh/M0249360.html","Name":"OPC 14597","Ref":122},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":123},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":151},{"Id":"M0001384","Link":"https://id.nlm.nih.gov/mesh/M0001384.html","Name":"Antidepressive Agents","Ref":152},{"Id":"M0021770","Link":"https://id.nlm.nih.gov/mesh/M0021770.html","Name":"Antipsychotic Agents","Ref":153},{"Id":"M0026368","Link":"https://id.nlm.nih.gov/mesh/M0026368.html","Name":"Serotonin 5-HT1 Receptor Agonists","Ref":154},{"Id":"M0027733","Link":"https://id.nlm.nih.gov/mesh/M0027733.html","Name":"Dopamine Agonists","Ref":155},{"Id":"M0544718","Link":"https://id.nlm.nih.gov/mesh/M0544718.html","Name":"Serotonin 5-HT2 Receptor Antagonists","Ref":156},{"Id":"M0587495","Link":"https://id.nlm.nih.gov/mesh/M0587495.html","Name":"Dopamine D2 Receptor Antagonists","Ref":157}],"MeSH Pharmacological Classification":[{"Id":"M0001384","Link":"https://id.nlm.nih.gov/mesh/M0001384.html","Name":"Antidepressive Agent","Ref":152},{"Id":"M0021770","Link":"https://id.nlm.nih.gov/mesh/M0021770.html","Name":"Antipsychotic Agent","Ref":153},{"Id":"M0026368","Link":"https://id.nlm.nih.gov/mesh/M0026368.html","Name":"Serotonin 5-HT1 Receptor Agonist","Ref":154},{"Id":"M0027733","Link":"https://id.nlm.nih.gov/mesh/M0027733.html","Name":"Dopamine Agonist","Ref":155},{"Id":"M0544718","Link":"https://id.nlm.nih.gov/mesh/M0544718.html","Name":"Serotonin 5-HT2 Receptor Antagonist","Ref":156},{"Id":"M0587495","Link":"https://id.nlm.nih.gov/mesh/M0587495.html","Name":"Dopamine D2 Receptor Antagonist","Ref":157}],"Mechanism of Action":"The antipsychotic action of aripiprazole is likely due to its partial agonist activity on D2 and 5-HT\u003csub\u003e1A\u003c/sub\u003e receptors as well as its antagonist activity at 5-HT\u003csub\u003e2A\u003c/sub\u003e receptors; however, the exact mechanism has not been fully elucidated. One of the mechanisms that have been proposed is that aripiprazole both stimulates and inhibits dopamine as it engages the D2 receptor. It lowers dopamine neuronal firing at high dopamine concentrations and increases dopamine firing at low concentrations. Its partial agonist activity gives aripiprazole an intermediate level of dopaminergic neuronal tone between full agonist and antagonist of the D2 receptor. In addition, some adverse effects may be due to action on other receptors. For example, orthostatic hypotension may be explained by antagonism of the adrenergic alpha-1 receptors.","Melting Point":"137-140","Metabolism/Metabolites":"Aripiprazole is metabolized primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for the dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in systemic circulation. At steady-state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.","MolecularFormula":"C\u003csub\u003e23\u003c/sub\u003eH\u003csub\u003e27\u003c/sub\u003eCl\u003csub\u003e2\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"448.4 g/mol","Pharmacodynamics":"Aripiprazole exhibits high affinity for dopamine D\u003csub\u003e2\u003c/sub\u003e and D\u003csub\u003e3\u003c/sub\u003e, serotonin 5-HT\u003csub\u003e1a\u003c/sub\u003e and 5-HT\u003csub\u003e2a\u003c/sub\u003e receptors (Ki values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively), moderate affinity for dopamine D\u003csub\u003e4\u003c/sub\u003e, serotonin 5-HT\u003csub\u003e2c\u003c/sub\u003e and 5-HT\u003csub\u003e7\u003c/sub\u003e, alpha\u003csub\u003e1\u003c/sub\u003e-adrenergic and histamine H\u003csub\u003e1\u003c/sub\u003e receptors (Ki values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC\u003csub\u003e50\u003c/sub\u003e\u003e1000 nM).","Physical Description":"Solid","PubChemId":60795,"Record Description":["LiverTox|CNS|Antipsychotic|Atypical"],"Records":{"UNII":{"Impurities":["deschloro aripiprazole","aripiprazole diquinoline butanediol","desethylene aripiprazole","aripiprazole n1-oxide","dehydroaripiprazole","7,7'-((oxybis(butane-4,1-diyl))bis(oxy))bis(3,4-dihydroquinolin-2(1h)-one)","2-deschloro aripiprazole","7-(4-hydroxybutoxy)-3,4-dihydroquinolin-2(1h)-one","aripiprazole dimer","1-(2,3-dichlorophenyl)piperazine","7-hydroxy-3,4-dihydrocarbostyril","3,4-dihydro-7-(4-iodobutoxy)-2(1h)-quinolinone"]}},"RefChem":"5563","RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Aripiprazole","Name":"Aripiprazole","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q411188","Name":"Aripiprazole","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB01238","Name":"Aripiprazole","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/60795","Name":"Aripiprazole","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=129722-12-9","Name":"Aripiprazole","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005042","Name":"Aripiprazole","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D01164","Name":"Aripiprazole","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/82VFR53I78","Name":"Aripiprazole","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID3046083","Name":"Aripiprazole","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 60795, Aripiprazole. Accessed May 6, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/60795\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/60795\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Aripiprazole. UNII: 82VFR53I78. Global Substance Registration System. Accessed May 6, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/82VFR53I78\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/82VFR53I78\u003c/a\u003e","ARIPENA (Sun Pharma ANZ Pty Ltd). Therapeutic Goods Administration, Government of Australia. . Accessed May 6, 2026. \u003ca href=https://www.tga.gov.au/resources/prescription-medicines-registrations/aripena-sun-pharma-anz-pty-ltd\u003ehttps://www.tga.gov.au/resources/prescription-medicines-registrations/aripena-sun-pharma-anz-pty-ltd\u003c/a\u003e"],"SMILES":"C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl","SaltData":[{"AcidCount":1,"Amine":"Aripiprazole","AmineCount":1,"Formula":"O","Name":"monohydrate","RName":"monohydrate","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 119.31 211.929\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h120v212H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m93.439 41.183.004-15.238M93.443 25.945l-13.195-7.624\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m79.028 19.025.005-12.023M81.467 19.025l.004-12.022\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m79.033 7.002-.002 6.011M81.471 7.003l-.002 6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m80.248 18.321-10.047 5.795M67.045 29.785l-.007 11.39\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m80.241 48.803-13.203-7.628M77.803 50.211l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m93.439 41.183-13.198 7.62M80.241 48.803l.005 15.249\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m67.048 71.672 13.198-7.62M67.048 68.856l10.759-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"m67.048 71.672-13.203-7.629\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.84 48.795.005 15.248M56.279 50.202l.003 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m67.038 41.175-13.198 7.62M53.845 64.043l-9.92 5.728M40.646 75.585v11.318M40.646 86.903l-13.198 7.62M27.448 94.523v15.24M27.448 109.763l-13.198 7.62M14.25 117.383v11.39M11.097 134.444 1.046 140.25M1.046 140.25l-.008 15.248M1.038 155.498l10.044 5.801M17.388 161.299l10.052-5.805M27.44 155.494l.007-15.249M17.403 134.444l10.044 5.801M14.235 166.97v11.39\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.44 185.987-13.205-7.627M25.002 187.394l-10.767-6.218\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.44 185.987.007 15.248\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.25 208.857 13.197-7.622M14.25 206.041l10.758-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.25 208.857-13.204-7.626\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 185.982.008 15.249M3.477 187.389l.006 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.235 178.36-13.197 7.622M27.447 201.235l10.255 5.916M27.44 185.987l10.24-5.915\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M82.513 3.078q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881T80.268.56q.733 0 1.233.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452\" class=\"atom\"/\u003e\u003cg fill=\"#3050f8\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M68.988 28.385h-.72l-2.619-4.066h-.03l.03.595q.023.357.023.732v2.739h-.565v-4.9h.714l2.608 4.054h.029l-.017-.327-.024-.476q-.006-.262-.006-.482v-2.769h.577zM64.545 28.385h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M42.906 71.66q0 .756-.256 1.328-.256.565-.757.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881t1.274-.316q.732 0 1.232.316.501.309.757.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.452\" class=\"atom\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M16.191 135.073h-.721l-2.619-4.066h-.03l.03.595q.024.357.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578zM16.176 165.57h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.055h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.769h.578z\" class=\"atom\"/\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M41.142 206.874q-.786 0-1.239.53-.452.524-.452 1.447 0 .911.417 1.446.422.53 1.268.53.321 0 .607-.053.292-.06.565-.143v.536q-.273.101-.565.148-.292.054-.697.054-.744 0-1.25-.31-.5-.309-.75-.875-.25-.571-.25-1.339 0-.744.268-1.31.274-.565.804-.881.529-.321 1.28-.321.779 0 1.351.285l-.244.524q-.226-.101-.506-.184-.274-.084-.607-.084m2.756 4.424h-.601v-5.215h.601zM41.131 176.388q-.786 0-1.239.53-.452.524-.452 1.446 0 .911.417 1.447.422.53 1.268.53.321 0 .607-.054.292-.059.565-.143v.536q-.273.101-.565.149-.292.054-.697.054-.744 0-1.25-.31-.5-.31-.75-.875-.25-.572-.25-1.34 0-.744.268-1.309.274-.566.804-.881.53-.322 1.28-.322.779 0 1.351.286l-.244.524q-.226-.101-.506-.185-.274-.083-.607-.083m2.756 4.423h-.601v-5.215h.601z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m70.201 24.116 5.024-2.898M70.201 24.116l5.024-2.898M67.045 29.785l-.004 5.695M67.045 29.785l-.004 5.695\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m43.925 69.771 4.96-2.864M40.646 75.585v5.659\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"M14.25 128.773v-5.695M11.097 134.444l-5.026 2.903M11.082 161.299l-5.022-2.9M17.388 161.299l5.026-2.902M17.403 134.444l5.022 2.9M14.235 166.97v5.695\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m37.702 207.151-5.127-2.958M37.68 180.072l-5.12 2.957\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M118.75 105.252q0 .757-.256 1.328-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.751.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.232.316.5.309.756.875.256.565.256 1.327m-3.863 0q0 .923.386 1.459.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524-.392.524-.392 1.452M111.165 107.705h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619zM113.67 109.195h-1.943v-.3l.771-.779q.222-.222.372-.393.154-.175.232-.339.079-.168.079-.365 0-.243-.147-.368-.143-.128-.371-.128-.215 0-.379.075-.161.075-.328.207l-.193-.243q.171-.146.393-.246.225-.1.507-.1.411 0 .65.207t.239.575q0 .229-.096.432-.093.2-.265.397-.167.196-.393.418l-.614.603v.018h1.486z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Aripiprazole monohydrate","UNII":"O362MEQ7VR"}],"Salts":["monohydrate"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Brazil","ref":[],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"New Zealand","ref":[],"schedule":"Prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"0.00001%","Stability/Shelf Life":"Stable under recommended storage conditions.","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 94.481 211.929\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h95v212H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m93.439 41.183.004-15.238M93.443 25.945l-13.195-7.624\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m79.028 19.025.005-12.023M81.467 19.025l.004-12.022\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m79.033 7.002-.002 6.011M81.471 7.003l-.002 6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m80.248 18.321-10.047 5.795M67.045 29.785l-.007 11.39\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m80.241 48.803-13.203-7.628M77.803 50.211l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m93.439 41.183-13.198 7.62M80.241 48.803l.005 15.249\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m67.048 71.672 13.198-7.62M67.048 68.856l10.759-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"m67.048 71.672-13.203-7.629\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.84 48.795.005 15.248M56.279 50.202l.003 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m67.038 41.175-13.198 7.62M53.845 64.043l-9.92 5.728M40.646 75.585v11.318M40.646 86.903l-13.198 7.62M27.448 94.523v15.24M27.448 109.763l-13.198 7.62M14.25 117.383v11.39M11.097 134.444 1.046 140.25M1.046 140.25l-.008 15.248M1.038 155.498l10.044 5.801M17.388 161.299l10.052-5.805M27.44 155.494l.007-15.249M17.403 134.444l10.044 5.801M14.235 166.97v11.39\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.44 185.987-13.205-7.627M25.002 187.394l-10.767-6.218\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.44 185.987.007 15.248\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.25 208.857 13.197-7.622M14.25 206.041l10.758-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.25 208.857-13.204-7.626\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 185.982.008 15.249M3.477 187.389l.006 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.235 178.36-13.197 7.622M27.447 201.235l10.255 5.916M27.44 185.987l10.24-5.915\" class=\"bond\"/\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M82.513 3.078q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881T80.268.56q.733 0 1.233.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M68.988 28.385h-.72l-2.619-4.066h-.03l.03.595q.023.357.023.732v2.739h-.565v-4.9h.714l2.608 4.054h.029l-.017-.327-.024-.476q-.006-.262-.006-.482v-2.769h.577zM64.545 28.385h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M42.906 71.66q0 .756-.256 1.328-.256.565-.757.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881t1.274-.316q.732 0 1.232.316.501.309.757.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.928-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.452\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M16.191 135.073h-.721l-2.619-4.066h-.03l.03.595q.024.357.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578zM16.176 165.57h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.055h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.769h.578z\" class=\"atom\"/\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M41.142 206.874q-.786 0-1.239.53-.452.524-.452 1.447 0 .911.417 1.446.422.53 1.268.53.321 0 .607-.053.292-.06.565-.143v.536q-.273.101-.565.148-.292.054-.697.054-.744 0-1.25-.31-.5-.309-.75-.875-.25-.571-.25-1.339 0-.744.268-1.31.274-.565.804-.881.529-.321 1.28-.321.779 0 1.351.285l-.244.524q-.226-.101-.506-.184-.274-.084-.607-.084m2.756 4.424h-.601v-5.215h.601zM41.131 176.388q-.786 0-1.239.53-.452.524-.452 1.446 0 .911.417 1.447.422.53 1.268.53.321 0 .607-.054.292-.059.565-.143v.536q-.273.101-.565.149-.292.054-.697.054-.744 0-1.25-.31-.5-.31-.75-.875-.25-.572-.25-1.34 0-.744.268-1.309.274-.566.804-.881.53-.322 1.28-.322.779 0 1.351.286l-.244.524q-.226-.101-.506-.185-.274-.083-.607-.083m2.756 4.423h-.601v-5.215h.601z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m70.201 24.116 5.024-2.898M70.201 24.116l5.024-2.898M67.045 29.785l-.004 5.695M67.045 29.785l-.004 5.695\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m43.925 69.771 4.96-2.864M40.646 75.585v5.659\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"M14.25 128.773v-5.695M11.097 134.444l-5.026 2.903M11.082 161.299l-5.022-2.9M17.388 161.299l5.026-2.902M17.403 134.444l5.022 2.9M14.235 166.97v5.695\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m37.702 207.151-5.127-2.958M37.68 180.072l-5.12 2.957\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Antipsychotic Agents","Title":"Aripiprazole","Treatment":"No specific information is available on the treatment of overdose with aripiprazole. An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers. Consider charcoal and hemodialysis. (A308)","UNII":"82VFR53I78","Wikidata":"Q411188","Wikipedia":"Aripiprazole","XLogP":4.6}